Peter N. Kellogg - 20 May 2026 Form 4 Insider Report for ALNYLAM PHARMACEUTICALS, INC. (ALNY)

Source evidence Original filing metadata and source links for verification. 4 source fields
SEC form
4
Accepted by SEC
22 May 2026, 16:12:58 UTC
Prior SEC filing
12 May 2025
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
Brett Budzinski, Attorney-in-Fact For: Peter N. Kellogg

Key filing fact

Peter N. Kellogg filed Form 4 for ALNYLAM PHARMACEUTICALS, INC. (ALNY) on 22 May 2026.

Key facts

  • This page summarizes Peter N. Kellogg's Form 4 filing for ALNYLAM PHARMACEUTICALS, INC. (ALNY).
  • 2 reported transactions and 1 derivative row are listed below.
  • Accepted by SEC: 22 May 2026, 16:12.

Change

  • Previous filing in this sequence was filed on 12 May 2025.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001226287 Primary reporting owner

KELLOGG PETER N

Relationship
Director
Address
675 WEST KENDALL STREET, CAMBRIDGE
Signature
Brett Budzinski, Attorney-in-Fact For: Peter N. Kellogg
Signature date
22 May 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ALNY transaction

Common Stock

Award

Transaction value
Shares
+671
Change %
+87%
Price
$0.000000*
Shares after
1,446
Date
20 May 2026
Ownership
Direct
Footnotes
F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ALNY transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares
+1,441
Change %
Price
$0.000000*
Shares after
1,441
Date
20 May 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
1,441
Exercise price
$298.48
Footnotes
F2
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

These shares are represented by restricted stock units (RSUs) granted under the Second Amended and Restated 2018 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of common stock. The RSUs will vest in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date.

Footnote F2

The stock option will vest in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .